Y. Kulyaba

Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL

T. Robak, K. Kuliczkowski, K. Warzocha, 2017, Leukemia & lymphoma.

Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial

T. Robak, K. Kuliczkowski, K. Warzocha, 2017, Leukemia & lymphoma.

Phase III, randomized study of ofatumumab versus physicians’ choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia

M. Steurer, A. Schuh, M. Montillo, 2016, Leukemia & lymphoma.

Abstract GS3-02: GS3-02 Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial

P. Neven, Y. Hotko, H. Denys, 2023, Cancer Research.

LBA54 Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial

I. Lowy, M. Gumus, M. Schenker, 2022, Annals of Oncology.

First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial

I. Lowy, I. Bondarenko, M. Schenker, 2023, The Lancet Oncology.